PMID- 26771762
OWN - NLM
STAT- MEDLINE
DCOM- 20160801
LR  - 20220330
IS  - 1097-0045 (Electronic)
IS  - 0270-4137 (Linking)
VI  - 76
IP  - 6
DP  - 2016 May
TI  - MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate 
      cancer.
PG  - 543-51
LID - 10.1002/pros.23143 [doi]
AB  - BACKGROUND: It is known that microRNAs (miRNAs) are a class of small, non-coding 
      RNAs that act as key regulators in various physiological and pathological 
      processes. However, the regulatory mechanisms involving miRNAs in prostate cancer 
      remain largely unknown. Here, we found that miR-103 is down-regulated in prostate 
      cancer and closely associated with tumor proliferation and migration. Our 
      objective was to explore the role of the miR-103 in prostate cancer. METHODS: In 
      this study, we measured miR-103 level using real-time polymerase chain reaction 
      in the human prostate cancer cell lines, including PC-3, LNCap, 22Rv1, DU145, and 
      the normal prostate epithelium cell line RWPE-1, a total of 25 pairs of primary 
      prostate cancer tissues and adjacent non-cancerous tissues (NCTs) were measured 
      also. In addition, over-expression of miR-103 in prostate cancer cell lines to 
      determine the role of miR-103 in prostate cancer. RESULTS: We found that miR-103 
      is down-regulated in prostate cancer and closely associated with tumor 
      proliferation and migration. In addition, over-expression of miR-103 apparently 
      inhibits prostate cancer cell proliferation and migration in vitro. 
      Gain-of-function in vitro experiments further show that miR-103 mimics 
      significantly inhibited prostate cancer cell proliferation, invasion and increase 
      the cell cycle in G1 phase, while promoted cell apoptosis. Subsequent 
      dual-luciferase reporter assay identified one of the proto-oncogene PDCD10 as 
      direct target of miR-103. CONCLUSIONS: Therefore, our data collectively 
      demonstrate that miR-103 is a proto-oncogene miRNA that can suppress prostate 
      cancer proliferation and migration by down-regulating the oncogene PDCD10, 
      indicating that miR-103 may represent a new potential diagnostic and therapeutic 
      target for prostate cancer treatment.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Fu, Xiaoliang
AU  - Fu X
AD  - Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an, China.
FAU - Su, Yansheng
AU  - Su Y
AD  - The Chinese People's Liberation Army 323 hospital, Xi'an, China.
FAU - Lu, Lu
AU  - Lu L
AD  - Armed Police Hospital of Shaanxi, Xi'an, China.
FAU - Wang, Dong
AU  - Wang D
AD  - Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an, China.
FAU - Wang, He
AU  - Wang H
AD  - Departmentof Urology, Xi'an Tangdu Hospital, The Fourth Military Medical 
      University, Xi'an, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160115
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (MAS1 protein, human)
RN  - 0 (MIRN103 microRNA, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (MicroRNAs)
RN  - 0 (PDCD10 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Proto-Oncogene Proteins)
SB  - IM
MH  - Apoptosis/genetics
MH  - Apoptosis Regulatory Proteins/*genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Membrane Proteins/*genetics
MH  - MicroRNAs/*genetics
MH  - *Prostatic Neoplasms/genetics/metabolism/pathology
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins/*genetics
MH  - Up-Regulation
OTO - NOTNLM
OT  - PDCD10
OT  - miR-103
OT  - migration
OT  - proliferation
OT  - prostate cancer
EDAT- 2016/01/16 06:00
MHDA- 2016/08/02 06:00
CRDT- 2016/01/16 06:00
PHST- 2015/09/09 00:00 [received]
PHST- 2015/12/15 00:00 [accepted]
PHST- 2016/01/16 06:00 [entrez]
PHST- 2016/01/16 06:00 [pubmed]
PHST- 2016/08/02 06:00 [medline]
AID - 10.1002/pros.23143 [doi]
PST - ppublish
SO  - Prostate. 2016 May;76(6):543-51. doi: 10.1002/pros.23143. Epub 2016 Jan 15.